Skip to main content
XOMA Royalty Corp logo

XOMA Royalty Corp — Investor Relations & Filings

Ticker · XOMA ISIN · US98419J3059 US Financial and insurance activities
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2026-01-14 Director's Dealing
Country US United States of America
Listing US XOMA

About XOMA Royalty Corp

https://xoma.com/

XOMA Royalty Corp. is a biotech royalty aggregator that acquires economic rights to potential future milestone and royalty payments. The company's portfolio consists of assets associated with pre-commercial clinical candidates being developed by various pharmaceutical and biotech partners. In exchange for these economic rights, XOMA provides its partners with non-dilutive, non-recourse capital to fund their internal drug development programs. This portfolio-based strategy, encompassing over 120 assets, is designed to diversify risk away from single-asset clinical outcomes. XOMA focuses on managing these royalty assets rather than direct drug development.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2026-01-14 English
SC TO-T/A Filing
M&A Activity Classification · 95% confidence The document is a Schedule TO Amendment No. 1 filing related to a tender offer under the Securities Exchange Act of 1934. It details an amendment to the expiration date of a tender offer by XOMA Royalty Corporation and XRA 7 Corp. to acquire shares of Generation Bio Co. The document is a regulatory filing specifically about a tender offer transaction, which aligns with merger and acquisition activity filings. The presence of terms like 'Tender Offer Statement,' 'Schedule TO,' and detailed transaction terms confirms this is related to M&A activity. The document is not a full merger proxy statement or tender offer communication but an amendment to a tender offer filing, which fits best under the M&A Activity category (TAR). The document length is 4265 characters, which is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is TAR with high confidence.
2026-01-12 English
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 12, 2026. It announces the availability of an updated corporate presentation attached as Exhibit 99.1. The text explicitly states that the information is being furnished and is not a full report but an update or disclosure. The document length is 3669 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is the corporate presentation, which is a detailed presentation for investors focusing on financials, strategy, and market position. Therefore, the document is best classified as an Investor Presentation (IP).
2026-01-12 English
SC TO-T Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under the Securities Exchange Act of 1934. It details a tender offer by XOMA Royalty Corporation and its subsidiary to acquire shares of Generation Bio Co. The document includes terms of the transaction, background, identity of filing persons, and references to the Offer to Purchase and Merger Agreement. It is a regulatory filing specifically related to a tender offer transaction, not a general report, earnings release, or proxy statement. The document is lengthy (over 13,000 characters) and contains detailed transaction information, consistent with a tender offer filing. This matches the definition of a Merger & Acquisition (MA) filing, which includes tender-offer forms such as Schedule TO. Therefore, the correct classification is MA.
2026-01-09 English
SC TO-C Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing under Rule 14d-100 of the Securities Exchange Act of 1934, which is a tender offer statement. It relates to a planned tender offer by XOMA Royalty Corporation and its subsidiary to purchase shares of Generation Bio Co. The document includes detailed information about the tender offer, references to the Agreement and Plan of Merger, and forward-looking statements. It also mentions that the actual Offer materials will be filed later on Schedule TO and Schedule 14D-9. This type of filing is specifically related to merger and acquisition activity, particularly tender offers. Therefore, the document fits the category of M&A Activity (TAR). The document length (9699 characters) and content confirm it is a full filing, not just an announcement or certification.
2025-12-16 English
4 Filing
Director's Dealing
2025-12-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.